The National Academy of Inventors has honored four academic inventors in Houston with their annual professional distinction. Photos courtesy

Four professors from the University of Houston and University of Texas MD Anderson Cancer Center have been admitted as fellows to the National Academy of Inventors.

From UH, Vincent Donnelly, Moores professor of Chemical and Biomolecular Engineering, and Christine Ehlig-Economides, Hugh Roy and Lillie Cranz Cullen Distinguished university chair of Petroleum Engineering, received the Fellows honor, which is the highest professional distinction awarded to academic inventors.

UH now has 39 professors who are either Fellows or Senior Members of the NAI. Donnelly and Ehlig-Economides will be inducted as NAI fellows at the NAI 13th annual meeting on June 18 in Raleigh, North Carolina.

“The remarkable contributions of the two new NAI Fellows from the University of Houston have left a lasting imprint, earning them high esteem in their respective fields,” Ramanan Krishnamoorti, vice president for research and technology at UH, says in a statement. “Their work stands as a testament to the extraordinary impact inventors can have, reflecting a standard of excellence that truly sets them apart.”

Donnelly, who is considered a pioneer in plasma science with applications to microelectronics and nanotechnology, was elevated to Fellow for his research on complex plasma systems used in the making of microchips. Ehlig-Economides was elevated to NAI fellow for her vital research leading to innovative solutions in the energy and industrial fields. Ehlig-Economides was also the first woman in the United States to earn a doctorate degree in petroleum engineering.

Two other Houston instructors from the University of Texas MD Anderson Cancer Center will be inducted to the program in the new year. Jeffrey H. Siewerdsen, professor within the department of Imaging Physics and the Division of Diagnostic Imaging, and Anil Sood, professor and vice chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA.

Some other notable Texas honorees among the 2024 appointees include:

  • Mark Benden, Texas A&M University
  • Arumugam Manthiram, the University of Texas at Austin
  • Werner Kuhr, Texas Tech University
  • Balakrishna Haridas, Texas A&M University
  • P.Reddy, Texas Tech University Health Sciences Center

“This year’s class of NAI Fellows showcases the caliber of researchers that are found within the innovation ecosystem. Each of these individuals are making significant contributions to both science and society through their work,” Dr. Paul R. Sanberg, president of the NAI, says in the release. “This new class, in conjunction with our existing Fellows, are creating innovations that are driving crucial advancements across a variety of disciplines and are stimulating the global and national economy in immeasurable ways as they move these technologies from lab to marketplace.

UH also ranks 60th on the National Academy of Inventors’ list of the top 100 universities for utility patents granted last year in the U.S. In 2022, UH received 32 utility patents. The university explains that utility patents are among the world’s most valuable assets because they give inventors exclusive commercial rights for producing and using their technology.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”